The Dental and Pharmaceutical Benefits Agency (Tandvårds Läkemedelförmånsverketthe, TLV) has a mission to perform health economic evaluations of medical devices.
These economic evaluations do not have a direct impact on reimbursement, although they influence decision-making in the County Councils regarding the use of the evaluated medical technologies and could influence changes in the reimbursement system of medical devices in Sweden.
In October of 2018, the TLV has published a completed health economic evaluation regarding the clinical efficacy and cost-effectiveness of the insulin pump system MiniMed 670G in comparison to MiniMed 640G device.
The following conclusions were provided:
- TLV believes that the use of the MiniMed 670G in comparison to the MiniMed 640G in patients with type 1 Diabetes can increase the patients’ quality of life due to reduced concern for hypoglycemia, increased comfort, and fewer complications. However, the company has not submitted any documents, where this quality of life benefit was quantified
- The use of MiniMed 670G leads to the increased cost per patient in 1,000 SEK per year. TLV estimates that this cost is low in relation to the assumed benefit of the MiniMed 670G compared to the MiniMed 640G
- Despite the uncertainties regarding the patients’ quality of life, TLV believes that it is likely that the switch from the MiniMed 640G to the MiniMed 670G is related to potential cost benefits
See the full details in Swedish here.
Subscribe to our newsletter delivered every second week not to miss important reimbursement information.